Ratings Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8541

Market Closed - OTC Markets Other stock markets 02:09:48 2024-06-05 pm EDT			5-day change	1st Jan Change
1.84 ^USD	0.00%		-12.38%	-67.96%

May. 20	Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	CI
May. 15	Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
YIELD10 BIOSCIENCE, INC.	-67.96%	1.18M	-
MODERNA, INC.	+55.70%	55.7B	B-
LONZA GROUP AG	+41.08%	39.91B	A
IQVIA HOLDINGS INC.	-5.39%	39.57B	B
CELLTRION, INC.	-5.56%	28.16B	C
ICON PUBLIC LIMITED COMPANY	+16.46%	26.3B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	18.94B	B
MEDPACE HOLDINGS, INC.	+33.03%	12.17B	C+
UNITED THERAPEUTICS CORPORATION	+25.85%	12.12B	B+
BIO-TECHNE CORPORATION	+2.72%	12.12B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes